Supportive Oligonucleotide Technique (SOT) has the ability to induce apoptosis, or cell death, in cancer cells.
What are oligonucleotides?
Oligonucleotides are made up of nucleotides, which are the building blocks of DNA and RNA. They can be made from either DNA or RNA, depending on their purpose. Oligonucleotides are usually between 10 and 100 nucleotides long.
Oligonucleotides work by targeting and destroying specific cells in the body. This makes them a valuable tool for treating many diseases, including cancer and cystic fibrosis.
Oligonucleotides can be used to target and destroy cancer cells without harming healthy cells nearby. This makes them a valuable tool for treating many types of cancer.
How do oligonucleotides target cancer cells?
The mechanism of how oligonucleotides target cancer cells is still being studied. However, it is thought that they work by entering the cells and destroying their DNA. This stops the cells from dividing and growing, which eventually leads to their death. Oligonucleotides can also be used to deliver chemotherapy drugs to cancer cells. This allows the drugs to kill the cancer cells more effectively.
One common use of oligonucleotides is to target mRNA. mRNA is a molecule that carries the genetic information from the nucleus of a cell to the rest of the cell. It is responsible for translating the genetic code into proteins. When oligonucleotides target mRNA, they can prevent it from being translated into proteins. This can stop the cell from dividing and growing, which eventually leads to its death.
We use mRNA expression fingerprinting in our clinic to identify certain gene expression patterns as targets. Based on this analysis of an individual’s Circulating Cancer Tumor Cells (CTSs), Circulating Cancer Stem Cells (CSCs), and occasionally from biopsies of the tumor, we generate the Supportive Oligonucleotide Technique.
SOT will remain active in the bloodstream for approximately 14-16 weeks per dose because the body is unable to recognize and destroy it. For this reason, only 3 SOT doses are allowed in any 12-month period from the date of the first dose to avoid an over-accumulation of these molecules in the body. More doses may be administered after a year, if necessary.
SOT will work 24/7 and has no decreased efficacy with any concurrent technique except chemotherapy and/or radiation.
The goal for SOT is to have a maximum of less than 2 circulating cancer tumor cells or cancer stem cells per mL. Repetitive scans and blood markers throughout the treatment will allow us to see if the tumor is stable, growing, or shrinking.